Phase 2 Hematopoietic Stem Cell Transplant Clinical Trials
13 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–13 of 13 trials
Recruiting
Phase 1Phase 2
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell Transplantation
National Cancer Institute (NCI)260 enrolled2 locationsNCT05436418
Recruiting
Phase 2
Ivosidenib as Post-HSCT Maintenance for AML
Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled4 locationsNCT06707493
Recruiting
Phase 2
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Hematologic MalignanciesHematopoietic Stem Cell Transplant (HSCT)
Pulmotect, Inc.100 enrolled11 locationsNCT06665100
Recruiting
Phase 2
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Hematopoietic Stem Cell TransplantationImmunodeficiency
National Cancer Institute (NCI)54 enrolled1 locationNCT05027945
Recruiting
Phase 2
Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients
Oral MucositisHematopoietic Stem Cell TransplantationStomatitis+1 more
The First Affiliated Hospital of Soochow University22 enrolled1 locationNCT07400328
Recruiting
Phase 1Phase 2
A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.
Acute Leukemia, High RiskMyelodysplastic Syndromes, High RiskHematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor
Ciusss de L'Est de l'Île de Montréal7 enrolled1 locationNCT07301866
Recruiting
Phase 2
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
ALLMRD-positiveHematopoietic Stem Cell Transplantation
Sheng-Li Xue, MD42 enrolled1 locationNCT05940961
Recruiting
Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Phase 2
Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia
Acute LeukemiaMenin InhibitorsPost Hematopoietic Stem Cell Transplantation+4 more
The First Affiliated Hospital of Soochow University60 enrolled1 locationNCT07101497
Recruiting
Phase 2
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
RelapseT-cell Acute Lymphoblastic LeukemiaALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine59 enrolled1 locationNCT06686108
Recruiting
Phase 2
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
Hematopoietic Stem Cell TransplantationThrombotic Microangiopathies
Omeros Corporation18 enrolled16 locationsNCT05855083
Recruiting
Phase 2
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression
Refractory Idiopathic Aplastic AnemiaHaploidentical Allogeneic Hematopoietic Stem Cell Transplantation
Assistance Publique - Hôpitaux de Paris31 enrolled35 locationsNCT05126849
Recruiting
Phase 2
An open label, study to evaluate the safety of Cannabidiol (CBD) for the prevention of Acute Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic cell transplantation.
Acute Graft Versus Host DiseaseHematopoietic Stem Cell Transplantation
Kalytera Therapeutics Israel Ltd36 enrolled2 locationsACTRN12619000623190